Targeted Therapy (Tyrosine Kinase Inhibitors)

Introduction / Overview

Tyrosine kinase inhibitors (TKIs) constitute a major class of targeted antineoplastic agents that interfere with intracellular signaling pathways pivotal for cellular proliferation, survival, and angiogenesis. By selectively inhibiting the ATP‑binding sites of receptor or non‑receptor tyrosine kinases, TKIs disrupt oncogenic signaling cascades that are frequently dysregulated in malignancies. The clinical success of TKIs, exemplified by imatinib in chronic myeloid leukemia (CML) and epidermal growth factor receptor (EGFR) inhibitors in non‑small cell lung cancer (NSCLC), has transformed the therapeutic landscape of many cancers, shifting the paradigm from conventional cytotoxic chemotherapy to precision medicine.

Given the evolving drug approvals and the expanding indications of TKIs, a comprehensive understanding of their pharmacology is essential for both medical and pharmacy students. The following chapter delineates the classification, mechanism of action, pharmacokinetic properties, therapeutic applications, adverse effect profiles, drug interactions, and special population considerations pertinent to TKIs. This knowledge base will support informed clinical decision‑making and patient management.

• Identify the principal classes of tyrosine kinase inhibitors and their molecular targets.
• Explain the pharmacodynamic mechanisms by which TKIs exert antineoplastic effects.
• Describe the absorption, distribution, metabolism, and excretion characteristics of representative TKIs.
• Summarize approved indications and common off‑label uses of TKIs.
• Recognize major adverse effects, drug interactions, and considerations for special populations.

Classification

Drug Classes and Categories

TKIs are broadly classified into two categories based on their target specificity:

• Receptor Tyrosine Kinase Inhibitors (RTKIs) – Target extracellular domain–associated kinases (e.g., EGFR, HER2, VEGFR, PDGFR). Examples include gefitinib, erlotinib, sunitinib, and pazopanib.
• Non‑Receptor Tyrosine Kinase Inhibitors (NRTKIs) – Target intracellular kinases that are not membrane‑bound (e.g., BCR‑ABL, c‑KIT, FLT3). Examples include imatinib, dasatinib, nilotinib, and midostaurin.

Chemical Classification

From a chemical standpoint, TKIs are largely heterocyclic molecules that mimic the adenine moiety of ATP, enabling competitive inhibition of the kinase ATP‑binding pocket. Structural variations confer differing degrees of selectivity, potency, and pharmacokinetic attributes. Representative chemical scaffolds include:

• Anthraniloyl and quinazoline derivatives (e.g., gefitinib, erlotinib).
• Imidazopyrimidine and benzylguanidinium structures (e.g., imatinib, dasatinib).
• Triazolopyrimidines (e.g., vandetanib).
• Pyrrolopyrimidines and pyrazolopyrimidines (e.g., sorafenib, regorafenib).

Mechanism of Action

Pharmacodynamics

Tumorigenic signaling frequently involves the phosphorylation of tyrosine residues within protein substrates, a process catalyzed by tyrosine kinases. TKIs competitively bind to the ATP‑binding cleft of these enzymes, thereby preventing phosphorylation events that propagate downstream signaling pathways such as RAS‑RAF‑MEK‑ERK, PI3K‑AKT, and JAK‑STAT. The inhibition of these pathways leads to cell cycle arrest, apoptosis, and decreased angiogenesis.

Receptor Interactions

RTKIs typically interfere with ligand‑induced dimerization or autophosphorylation of membrane‑bound receptors. For instance, EGFR TKIs (gefitinib, erlotinib) bind to the intracellular tyrosine kinase domain of EGFR, blocking its activation by epidermal growth factor. Similarly, VEGFR TKIs (sunitinib, sorafenib) inhibit receptor autophosphorylation, thereby attenuating angiogenic signaling.

Molecular and Cellular Mechanisms

In CML, the BCR‑ABL fusion protein constitutively activates tyrosine kinase activity independent of growth factor binding. Imatinib binds to the ATP‑binding pocket of BCR‑ABL, stabilizing the inactive conformation and preventing downstream phosphorylation of substrates such as CRKL and Shc. This blockade diminishes proliferation of myeloid precursors and promotes apoptosis.

In NSCLC harboring EGFR mutations (e.g., exon 19 deletions, L858R), TKIs induce selective inhibition of mutant kinase activity, sparing wild‑type EGFR and thereby reducing toxicity. In melanoma, the BRAF V600E mutation leads to constitutive MAPK pathway activation; BRAF inhibitors (vemurafenib, dabrafenib) block the mutant kinase, arresting tumor growth.

Pharmacokinetics

Absorption

Most orally administered TKIs exhibit moderate to high oral bioavailability, although it can be influenced by food, gastric pH, and transporter activity. For example, imatinib demonstrates approximately 98% oral bioavailability, whereas gefitinib reaches about 30–40% in fasting conditions, increasing to ~50% when taken with food. Oral absorption may be limited by efflux transporters such as P‑gp and BCRP.

Distribution

TKIs are generally highly protein‑bound (≥90%), predominantly to albumin and alpha‑1‑acid glycoprotein. This high binding affinity can influence tissue penetration and drug–drug interactions. Volume of distribution varies: imatinib (≈ 400 L), gefitinib (≈ 4,200 L), and sorafenib (≈ 3,200 L). The extensive distribution allows for adequate tumor tissue exposure but also necessitates caution in patients with hypoalbuminemia.

Metabolism

Cytochrome P450 enzymes, particularly CYP3A4/5, are the principal metabolic pathways for many TKIs. Secondary pathways involve CYP1A2, CYP2D6, and UGT1A9. For instance, sorafenib is metabolized by CYP3A4 and CYP2C9, whereas imatinib undergoes N‑oxidation via CYP3A4 and CYP2C9. Metabolite activity varies: the M315 metabolite of gefitinib retains partial activity, while the N‑oxide of imatinib is inactive.

Excretion

Renal excretion is minimal for most TKIs, accounting for <10% of the dose. Excretion occurs primarily via biliary routes or fecal elimination. Some metabolites are excreted in urine; for example, the polar metabolite of erlotinib is eliminated renally. Knowledge of excretion pathways is vital when dosing in patients with renal impairment.

Half‑Life and Dosing Considerations

Half‑lives vary widely: imatinib (18–21 h), gefitinib (48–70 h), sorafenib (25–48 h), and dasatinib (3–4 h). Dosing schedules are thus tailored to achieve steady‑state concentrations while minimizing toxicity. Dose adjustments may be required in hepatic impairment; for example, sorafenib dose reduction is recommended in Child‑Pugh class B and C cirrhosis. In patients taking concomitant strong CYP3A4 inhibitors (ketoconazole, ritonavir), dose reduction or therapeutic drug monitoring may be necessary to avoid elevated plasma levels and adverse events.

Therapeutic Uses / Clinical Applications

Approved Indications

• Imatinib – Chronic myeloid leukemia (CML) in chronic and accelerated phases; Philadelphia chromosome‑positive acute lymphoblastic leukemia (ALL); gastrointestinal stromal tumors (GIST) with c‑KIT or PDGFRA mutations.
• Dasatinib – CML resistant or intolerant to imatinib; Philadelphia chromosome‑positive ALL.
• Nilotinib – CML resistant or intolerant to imatinib; GIST with c‑KIT exon 9 mutations.
• Gefitinib & Erlotinib – NSCLC with EGFR activating mutations; maintenance therapy in NSCLC with EGFR exon 19 deletion or L858R mutation.
• Osimertinib – NSCLC harboring EGFR T790M resistance mutation; adjuvant therapy in early‑stage EGFR‑positive NSCLC.
• Vemurafenib & Dabrafenib – Metastatic melanoma with BRAF V600E or V600K mutations.
• Trametinib – Metastatic melanoma with BRAF V600E/K in combination with dabrafenib.
• Sunitinib & Pazopanib – Renal cell carcinoma (RCC), gastrointestinal stromal tumors, and hepatocellular carcinoma (HCC).
• Sorafenib & Regorafenib – HCC; metastatic colorectal cancer (CRC) refractory to standard therapy.
• Midostaurin – Acute myeloid leukemia (AML) with FLT3 mutations.
• Olverembatinib – CML resistant to multiple TKIs (in selected jurisdictions).

Off‑Label Uses

TKIs are frequently employed off‑label for various malignancies where molecular profiling suggests targetable mutations. Examples include:

• Imatinib for dermatofibrosarcoma protuberans (DFSP) and desmoid tumors.
• Gefitinib for metastatic breast cancer with EGFR overexpression.
• Sunitinib for metastatic sarcomas and pancreatic neuroendocrine tumors.
• Dasatinib for solid tumors harboring SRC family kinase activation.

Off‑label use is guided by evidence from clinical trials, case series, or mechanistic rationale, and requires careful consideration of risk–benefit profiles.

Adverse Effects

Common Side Effects

• Hematologic toxicity – Neutropenia, thrombocytopenia, anemia (particularly with imatinib, dasatinib, nilotinib).
• Dermatologic reactions – Rash, pruritus, photosensitivity (notably with EGFR inhibitors).
• Gastrointestinal disturbances – Nausea, vomiting, diarrhea, mucositis (common with all TKIs).
• Edema and pleural effusion – Especially with imatinib, dasatinib, and sunitinib.
• Fatigue – Frequently reported across TKI classes.
• Hepatotoxicity – Elevated transaminases, cholestasis (sorafenib, regorafenib).
• Cardiovascular effects – Hypertension, QT prolongation (sunitinib, sorafenib).

Serious or Rare Adverse Reactions

• Myelosuppression – Grade 3/4 neutropenia or thrombocytopenia; requires dose interruption or reduction.
• Secondary malignancies – Rare cases of acute cutaneous lymphomas with imatinib.
• Pulmonary toxicity – Interstitial lung disease, pneumonitis (particularly with gefitinib, erlotinib).
• Severe dermatologic toxicity – Stevens–Johnson syndrome, toxic epidermal necrolysis (rare).
• Cardiovascular events – Heart failure exacerbation with nilotinib; arrhythmias with sorafenib.
• Gastrointestinal perforation – Rare but reported with sunitinib in colorectal cancers.

Black Box Warnings

• Imatinib: Potential for death due to cardiovascular events in patients with pre‑existing heart disease.
• Dasatinib: Pulmonary hypertension and pleural effusion with potential life‑threatening consequences.
• Sunitinib: Severe hypertension, cardiac ischemia, and severe skin reactions.
• Osimertinib: Severe interstitial lung disease, QT prolongation, and hepatotoxicity.

Drug Interactions

Major Drug‑Drug Interactions

• Cytochrome P450 modulators – Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) may elevate TKI plasma levels; strong CYP3A4 inducers (rifampin, carbamazepine) may reduce efficacy.
• Concomitant use with other TKIs or kinase inhibitors – Potential additive toxicities (e.g., overlapping cardiotoxicity).
• Anticoagulants – TKIs may inhibit platelet function; caution with warfarin or direct oral anticoagulants (DOACs).
• Hepatotoxic agents – Concurrent administration of hepatotoxic drugs (e.g., acetaminophen) may compound liver injury.
• Transporter inhibitors/inducers – P‑gp and BCRP modulators can influence absorption and clearance.

Contraindications

• Known hypersensitivity to the TKI or any component of the formulation.
• Severe hepatic impairment (Child‑Pugh class C) for agents contraindicated in hepatic dysfunction.
• Uncontrolled cardiac disease (e.g., recent myocardial infarction) for TKIs with significant cardiotoxicity.
• Pregnancy in the first trimester for agents with known teratogenicity (e.g., imatinib).

Special Considerations

Use in Pregnancy and Lactation

Most TKIs cross the placenta and may cause fetal harm, including teratogenicity, growth restriction, and embryopathy. Consequently, they are generally contraindicated during pregnancy, except in life‑threatening situations where benefits may outweigh risks and informed consent is obtained. Breastfeeding is contraindicated due to potential drug excretion into breast milk and maternal toxicity.

Pediatric Considerations

Pharmacokinetic data in children are limited; dosing is often weight‑based. Imatinib has been approved for pediatric CML and GIST, with dose adjustments for age and body surface area. Safety profiles are similar to adults but require vigilant monitoring for growth and developmental effects. Clinical trials are ongoing for pediatric indications in other TKIs.

Geriatric Considerations

Older adults may exhibit altered pharmacokinetics due to decreased hepatic clearance and renal function. Dose reductions or extended dosing intervals are sometimes warranted. Polypharmacy increases the risk of drug interactions, necessitating comprehensive medication reviews.

Renal and Hepatic Impairment

Renal impairment generally has minimal impact on TKI exposure; however, dose adjustments are recommended for agents with significant renal clearance (e.g., erlotinib). Hepatic impairment can markedly alter metabolism; for instance, sorafenib dose reductions are advised in Child‑Pugh class B/C. Monitoring of liver function tests is essential during therapy.

Summary / Key Points

• Tyrosine kinase inhibitors target dysregulated signaling pathways, offering a precision approach to antineoplastic therapy.
• Receptor and non‑receptor TKIs differ in target specificity and chemical scaffold, influencing pharmacokinetic and safety profiles.
• Pharmacodynamic action centers on ATP‑competitive inhibition of tyrosine kinases, disrupting downstream proliferative and survival pathways.
• Absorption is generally adequate orally, but food, transporters, and CYP3A4 activity can modulate bioavailability.
• Metabolism is predominantly via CYP3A4/5; concomitant inhibitors or inducers can substantially alter drug exposure.
• Approved indications span hematologic malignancies, solid tumors, and rare diseases, with off‑label use guided by molecular profiling.
• Common adverse effects include hematologic toxicity, dermatologic rash, GI disturbances, and edema; serious events such as cardiotoxicity and hepatotoxicity necessitate monitoring.
• Drug interactions, particularly involving CYP3A4 and transporter modulators, are clinically significant and may require dose adjustment or avoidance.
• Special populations—pregnant, lactating, pediatric, geriatric, and those with organ impairment—require individualized dosing and monitoring strategies.
• Ongoing research into combination therapies and novel TKIs promises to expand therapeutic horizons while refining safety profiles.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.